{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:34:10Z","timestamp":1790127250117,"version":"4.0.1"},"reference-count":37,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Chimeric antigen receptor T-cell therapy has revolutionized the treatment of relapsed\/refractory (R\/R) follicular lymphoma (FL). Real-world efficacy and toxicity data are needed because clinical trial populations are often unrepresentative. Therefore, we conducted a multicenter retrospective study of R\/R FL patients undergoing commercial axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) between 2021 and 2024. End points included efficacy measures (overall response rate [ORR], complete response rate [CRR], progression-free survival [PFS], and overall survival [OS]) and toxicity (rates of cytokine release syndrome [CRS] and immune effector cell\u2013associated neurotoxicity syndrome [ICANS]). Among 136 patients, 100 (74%) received axi-cel and 36 (26%) received tisa-cel. Axi-cel patients were younger than tisa-cel patients (median age, 60 vs 68 years; P = .001) and received bendamustine lymphodepletion less often than them (9% vs 33%; P&amp;lt; .001). Median follow-up was 14.4 months (range, 0.8-72.0 months). In the unweighted analysis, compared with tisa-cel, axi-cel was associated with higher ORR (96% vs 80%; P = .007), CRR (88% vs 71%; P = .024), and longer median PFS (30.5 months vs 11.9 months; P = .021). Median OS did not differ significantly between the 2 products (not reached vs 23.6 months; P = .061). The rates of CRS were comparable (75% vs 75%; P = .99), whereas ICANS occurred more frequently with axi-cel than with tisa-cel (42% vs 17%; P = .008). After inverse probability of treatment weighting, efficacy outcomes were largely similar, but axi-cel remained associated with significantly higher toxicity. In real-world settings, both axi-cel and tisa-cel demonstrated efficacy in patients with R\/R FL, although PFS was inferior to that reported in clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019115","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:46:29Z","timestamp":1772138789000},"page":"3757-3768","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Real-world outcomes and toxicities of CAR-T in relapsed\/refractory follicular lymphoma: a multicenter cohort study"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5765-8549","authenticated-orcid":false,"given":"John","family":"Sharp","sequence":"first","affiliation":[{"name":"1Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-1459","authenticated-orcid":false,"given":"Paolo","family":"Strati","sequence":"additional","affiliation":[{"name":"2MD Anderson Cancer Center, University of Texas, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh","family":"Bhatta","sequence":"additional","affiliation":[{"name":"1Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0863-9389","authenticated-orcid":false,"given":"Jennifer J.","family":"Huang","sequence":"additional","affiliation":[{"name":"3Fred Hutchinson Cancer Center, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Thomas","sequence":"additional","affiliation":[{"name":"4Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0786-8035","authenticated-orcid":false,"given":"Omar","family":"Elghawy","sequence":"additional","affiliation":[{"name":"4Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2804-0584","authenticated-orcid":false,"given":"Daniel","family":"Reef","sequence":"additional","affiliation":[{"name":"5Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0657-1328","authenticated-orcid":false,"given":"Alexander","family":"Gorzewski","sequence":"additional","affiliation":[{"name":"6Lurie Cancer Center, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Wang","sequence":"additional","affiliation":[{"name":"7Feinberg School of Medicine, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7917-5713","authenticated-orcid":false,"given":"Geoffrey","family":"Shouse","sequence":"additional","affiliation":[{"name":"8City of Hope Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Reinert","sequence":"additional","affiliation":[{"name":"9Anschutz Cancer Center, University of Colorado Cancer Center, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andinet","family":"Teferra","sequence":"additional","affiliation":[{"name":"10Masonic Cancer Center, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8147-4504","authenticated-orcid":false,"given":"Esteban Toro","family":"Velez","sequence":"additional","affiliation":[{"name":"11Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Pelcovits","sequence":"additional","affiliation":[{"name":"12Brown University Health Cancer Institute, Brown University, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0102-6491","authenticated-orcid":false,"given":"Thomas","family":"Ollila","sequence":"additional","affiliation":[{"name":"12Brown University Health Cancer Institute, Brown University, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Clark","sequence":"additional","affiliation":[{"name":"11Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Yazbeck","sequence":"additional","affiliation":[{"name":"11Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Maakaron","sequence":"additional","affiliation":[{"name":"10Masonic Cancer Center, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1930-152X","authenticated-orcid":false,"given":"Manali","family":"Kamdar","sequence":"additional","affiliation":[{"name":"9Anschutz Cancer Center, University of Colorado Cancer Center, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Fitzgerald","sequence":"additional","affiliation":[{"name":"13Huntsman Cancer Institute, University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Danilov","sequence":"additional","affiliation":[{"name":"8City of Hope Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Karmali","sequence":"additional","affiliation":[{"name":"6Lurie Cancer Center, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1346-3157","authenticated-orcid":false,"given":"Natalie S.","family":"Grover","sequence":"additional","affiliation":[{"name":"5Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3280-5271","authenticated-orcid":false,"given":"Stefan K.","family":"Barta","sequence":"additional","affiliation":[{"name":"4Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7603-6454","authenticated-orcid":false,"given":"Timothy J.","family":"Voorhees","sequence":"additional","affiliation":[{"name":"1Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5204-9445","authenticated-orcid":false,"given":"Andy I.","family":"Chen","sequence":"additional","affiliation":[{"name":"14Knight Cancer Institute, Oregon Health Sciences University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-6562","authenticated-orcid":false,"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[{"name":"3Fred Hutchinson Cancer Center, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-8299","authenticated-orcid":false,"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[{"name":"2MD Anderson Cancer Center, University of Texas, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-3457","authenticated-orcid":false,"given":"Narendranath","family":"Epperla","sequence":"additional","affiliation":[{"name":"1Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH"},{"name":"13Huntsman Cancer Institute, University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"issue":"4","key":"2026060911314292400_bib1","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.hoc.2020.02.001","article-title":"Epidemiology of follicular lymphoma","volume":"34","author":"Cerhan","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"issue":"suppl 5","key":"2026060911314292400_bib2","doi-asserted-by":"crossref","first-page":"v83","DOI":"10.1093\/annonc\/mdw400","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Dreyling","year":"2016","journal-title":"Ann Oncol"},{"issue":"7","key":"2026060911314292400_bib3","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"7","key":"2026060911314292400_bib4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer J"},{"key":"2026060911314292400_bib5","doi-asserted-by":"crossref","first-page":"e2300067","DOI":"10.1200\/CCI.23.00067","article-title":"Estimating the lifetime treatment burden of patients with follicular lymphoma: a retrospective study using real-world multicenter data","volume":"7","author":"Rajam\u00e4ki","year":"2023","journal-title":"JCO Clin Cancer Inform"},{"issue":"2","key":"2026060911314292400_bib6","doi-asserted-by":"crossref","first-page":"115","DOI":"10.36469\/jheor.2022.38070","article-title":"Treatment patterns of follicular lymphoma in the United States: a claims analysis","volume":"9","author":"Huntington","year":"2022","journal-title":"J Health Econ Outcomes Res"},{"issue":"1","key":"2026060911314292400_bib7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/hematology.2020000156","article-title":"How do I sequence therapy for follicular lymphoma?","volume":"2020","author":"Salles","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"2026060911314292400_bib8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-021-01113-2","article-title":"Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies","volume":"14","author":"Hanel","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"2","key":"2026060911314292400_bib9","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood.2024025699","article-title":"Building the future management of follicular lymphoma with T-cell\u2013redirecting strategies","volume":"145","author":"Iacoboni","year":"2025","journal-title":"Blood"},{"issue":"8","key":"2026060911314292400_bib10","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jtct.2025.05.014","article-title":"Current activity trends and outcomes in hematopoietic cell transplantation and cellular therapy \u2013 a report from the CIBMTR","volume":"31","author":"Spellman","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"2026060911314292400_bib11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"6","key":"2026060911314292400_bib12","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.2023021243","article-title":"Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5)","volume":"143","author":"Neelapu","year":"2024","journal-title":"Blood"},{"key":"2026060911314292400_bib13","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"issue":"17","key":"2026060911314292400_bib14","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood.2023021567","article-title":"Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update","volume":"143","author":"Dreyling","year":"2024","journal-title":"Blood"},{"issue":"8","key":"2026060911314292400_bib15","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat Med"},{"issue":"10","key":"2026060911314292400_bib16","doi-asserted-by":"crossref","first-page":"e674","DOI":"10.1016\/S2666-7568(22)00186-6","article-title":"Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43 895 trials and 5 685 738 individuals across 989 unique drugs and 286 conditions in England","volume":"3","author":"Tan","year":"2022","journal-title":"Lancet Healthy Longev"},{"issue":"1","key":"2026060911314292400_bib17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s12916-019-1427-1","article-title":"Representation of people with comorbidity and multimorbidity in clinical trials of novel drug therapies: an individual-level participant data analysis","volume":"17","author":"Hanlon","year":"2019","journal-title":"BMC Med"},{"issue":"suppl 1","key":"2026060911314292400_bib18","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1182\/blood-2018-99-113872","article-title":"Understanding the differences between clinical trial participants and real-world patients with non-Hodgkin lymphoma","volume":"132","author":"Fatola","year":"2018","journal-title":"Blood"},{"issue":"27","key":"2026060911314292400_bib19","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026060911314292400_bib20","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026060911314292400_bib21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2021.08.005","article-title":"Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma","volume":"157","author":"Alonso-\u00c1lvarez","year":"2021","journal-title":"Eur J Cancer"},{"issue":"suppl 1","key":"2026060911314292400_bib22","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2023-184653","article-title":"Real-word experience of CAR T-cells in patients with relapsed\/refractory follicular lymphoma: a Descart Registry Analysis from the Lysa","volume":"142","author":"Ysebaert","year":"2023","journal-title":"Blood"},{"issue":"16 suppl","key":"2026060911314292400_bib23","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.1200\/JCO.2023.41.16_suppl.7509","article-title":"Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory (R\/R) follicular lymphoma (FL)","volume":"41","author":"Jacobson","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026060911314292400_bib24","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1111\/bjh.70025","article-title":"Real-world experience with CAR-T therapy in relapsed and refractory follicular lymphoma","volume":"207","author":"Triantafilo","year":"2025","journal-title":"Br J Haematol"},{"issue":"6","key":"2026060911314292400_bib25","doi-asserted-by":"crossref","first-page":"584.e1","DOI":"10.1016\/j.jtct.2024.01.074","article-title":"Axicabtagene ciloleucel versus tisagenlecleucel for relapsed or refractory large B cell lymphoma: a systematic review and meta-analysis","volume":"30","author":"Gagelmann","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"17","key":"2026060911314292400_bib26","doi-asserted-by":"crossref","first-page":"5729","DOI":"10.7150\/jca.99427","article-title":"Comparison of the efficacy and safety of axi-cel and tisa-cel based on meta-analysis","volume":"15","author":"Liao","year":"2024","journal-title":"J Cancer"},{"issue":"1","key":"2026060911314292400_bib27","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3324\/haematol.2022.280805","article-title":"Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma","volume":"108","author":"Kwon","year":"2023","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2026060911314292400_bib28","doi-asserted-by":"crossref","first-page":"7411","DOI":"10.1182\/blood-2022-163726","article-title":"Biological differences between axi-cel and tisa-cel products and impacts on outcomes in lymphoma patients","volume":"140","author":"Tessoulin","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2026060911314292400_bib29","doi-asserted-by":"crossref","first-page":"e1049","DOI":"10.1002\/cti2.1049","article-title":"Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations","volume":"8","author":"Weinkove","year":"2019","journal-title":"Clin Transl Immunol"},{"issue":"10","key":"2026060911314292400_bib30","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/ajh.26301","article-title":"Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed\/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials","volume":"96","author":"Westin","year":"2021","journal-title":"Am J Hematol"},{"issue":"3","key":"2026060911314292400_bib31","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.immuni.2016.02.023","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T Cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"issue":"8","key":"2026060911314292400_bib32","doi-asserted-by":"crossref","first-page":"549.e1","DOI":"10.1016\/j.jtct.2025.03.012","article-title":"Comparative efficacy of bendamustine versus fludarabine\/cyclophosphamide for lymphodepletion before chimeric antigen receptor T-cell therapy in lymphoma","volume":"31","author":"Rao","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"2026060911314292400_bib33","doi-asserted-by":"crossref","first-page":"e008975","DOI":"10.1136\/jitc-2024-008975","article-title":"Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma","volume":"12","author":"Bharadwaj","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"3","key":"2026060911314292400_bib34","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1182\/bloodadvances.2023011492","article-title":"Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines","volume":"8","author":"Ghilardi","year":"2024","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2026060911314292400_bib35","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2024-200269","article-title":"Real world comparison of efficacy and safety of fludarabine-versus bendamustine-based lymphodepleting chemotherapy for CD19 chimeric antigen receptor (CAR) T-cell therapy in relapse\/refractory (r\/r) large B-cell lymphoma (LBCL)","volume":"144","author":"Ali","year":"2024","journal-title":"Blood"},{"issue":"9","key":"2026060911314292400_bib36","doi-asserted-by":"crossref","first-page":"581.e1","DOI":"10.1016\/j.jtct.2022.05.026","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large b cell lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"26","key":"2026060911314292400_bib37","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/11\/3757\/2523401\/blooda_adv-2025-019115-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/11\/3757\/2523401\/blooda_adv-2025-019115-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:31:51Z","timestamp":1781019111000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/11\/3757\/566869\/Real-world-outcomes-and-toxicities-of-CAR-T-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,6,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019115","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,9]]},"published":{"date-parts":[[2026,5,27]]}}}